BACKGROUND: Anthrax-associated shock is closely linked to lethal toxin (LT) release and is highly lethal despite conventional hemodynamic support. We investigated whether protective antigen-directed monoclonal antibody (PA-mAb) treatment further augments titrated hemodynamic support. METHODS AND RESULTS: Forty sedated, mechanically ventilated, instrumented canines challenged with anthrax LT were assigned to no treatment (controls), hemodynamic support alone (protocol-titrated fluids and norepinephrine), PA-mAb alone (administered at start of LT infusion [0 hours] or 9 or 12 hours later), or both, and observed for 96 hours. Although all 8 controls died, 2 of 8 animals receiving hemodynamic support alone survived (median survival times 65 vs 85 hours, respectively; P = .03). PA-mAb alone at 0 hour improved survival (5 of 5 animals survived), but efficacy decreased progressively with delayed treatment (9 hours, 2 of 3 survived; 12 hours, 0 of 4 survived) (P = .004 comparing survival across treatment times). However, combined treatment increased survival irrespective of PA-mAb administration time (0 hours, 4 of 5 animals; 9 hours, 3 of 3 animals; and 12 hours, 4 of 5 animals survived) (P = .95 comparing treatment times). Compared to hemodynamic support alone, when combined over PA-mAb treatment times (0, 9, and 12 hours), combination therapy produced higher survival (P = .008), central venous pressures, and left ventricular ejection fractions, and lower heart rates, norepinephrine requirements and fluid retention (P ≤ .03). CONCLUSIONS: PA-mAb may augment conventional hemodynamic support during anthrax LT-associated shock.
BACKGROUND:Anthrax-associated shock is closely linked to lethal toxin (LT) release and is highly lethal despite conventional hemodynamic support. We investigated whether protective antigen-directed monoclonal antibody (PA-mAb) treatment further augments titrated hemodynamic support. METHODS AND RESULTS: Forty sedated, mechanically ventilated, instrumented canines challenged with anthrax LT were assigned to no treatment (controls), hemodynamic support alone (protocol-titrated fluids and norepinephrine), PA-mAb alone (administered at start of LT infusion [0 hours] or 9 or 12 hours later), or both, and observed for 96 hours. Although all 8 controls died, 2 of 8 animals receiving hemodynamic support alone survived (median survival times 65 vs 85 hours, respectively; P = .03). PA-mAb alone at 0 hour improved survival (5 of 5 animals survived), but efficacy decreased progressively with delayed treatment (9 hours, 2 of 3 survived; 12 hours, 0 of 4 survived) (P = .004 comparing survival across treatment times). However, combined treatment increased survival irrespective of PA-mAb administration time (0 hours, 4 of 5 animals; 9 hours, 3 of 3 animals; and 12 hours, 4 of 5 animals survived) (P = .95 comparing treatment times). Compared to hemodynamic support alone, when combined over PA-mAb treatment times (0, 9, and 12 hours), combination therapy produced higher survival (P = .008), central venous pressures, and left ventricular ejection fractions, and lower heart rates, norepinephrine requirements and fluid retention (P ≤ .03). CONCLUSIONS: PA-mAb may augment conventional hemodynamic support during anthrax LT-associated shock.
Authors: Mark S Klempner; Elizabeth A Talbot; Susanna I Lee; Sherif Zaki; Mary Jane Ferraro Journal: N Engl J Med Date: 2010-08-19 Impact factor: 91.245
Authors: Laith Altaweel; Zhaochun Chen; Mahtab Moayeri; Xizhong Cui; Yan Li; Junwu Su; Yvonne Fitz; Syd Johnson; Stephen H Leppla; Robert Purcell; Peter Q Eichacker Journal: Crit Care Med Date: 2011-06 Impact factor: 7.598
Authors: Daniel A Sweeney; Xizhong Cui; Steven B Solomon; David A Vitberg; Thi S Migone; Dara Scher; Robert L Danner; Charles Natanson; G Mani Subramanian; Peter Q Eichacker Journal: J Infect Dis Date: 2010-11-10 Impact factor: 5.226
Authors: Linley E Watson; Jonathan Mock; Hind Lal; Guangrong Lu; Raymond W Bourdeau; Wei-Jen Tang; Stephen H Leppla; David E Dostal; Arthur E Frankel Journal: Front Biosci Date: 2007-05-01
Authors: Kevin Sherer; Yan Li; Xizhong Cui; Xuemei Li; Mani Subramanian; Michael W Laird; Mahtab Moayeri; Stephen H Leppla; Yvonne Fitz; Junwu Su; Peter Q Eichacker Journal: Crit Care Med Date: 2007-06 Impact factor: 7.598
Authors: Martha Triantafilou; Ahmed Uddin; Sebastien Maher; Nicholas Charalambous; Thomas S C Hamm; Ahmad Alsumaiti; Kathy Triantafilou Journal: Cell Microbiol Date: 2007-07-26 Impact factor: 3.715
Authors: Peter C Minneci; Katherine J Deans; Bernie Hansen; Chantal Parent; Chris Romines; Denise A Gonzales; Sai-Xia Ying; Peter Munson; Anthony F Suffredini; Jing Feng; Michael A Solomon; Steven M Banks; Steven J Kern; Robert L Danner; Peter Q Eichacker; Charles Natanson; Steven B Solomon Journal: Am J Physiol Heart Circ Physiol Date: 2007-07-20 Impact factor: 4.733
Authors: James J Walsh; Nicki Pesik; Conrad P Quinn; Veronica Urdaneta; Clare A Dykewicz; Anne E Boyer; Jeannette Guarner; Patricia Wilkins; Kim J Norville; John R Barr; Sherif R Zaki; Jean B Patel; Sarah P Reagan; James L Pirkle; Tracee A Treadwell; Nancy Rosenstein Messonnier; Lisa D Rotz; Richard F Meyer; David S Stephens Journal: Clin Infect Dis Date: 2007-02-26 Impact factor: 9.079
Authors: Machender R Kandadi; Yinan Hua; Heng Ma; Qun Li; Shu-ru Kuo; Arthur E Frankel; Jun Ren Journal: PLoS One Date: 2010-10-13 Impact factor: 3.240
Authors: Linley E Watson; Shu-Ru Kuo; Khurshed Katki; Tongyun Dang; Seong Kyu Park; David E Dostal; Wei-Jen Tang; Stephen H Leppla; Arthur E Frankel Journal: PLoS One Date: 2007-05-23 Impact factor: 3.240
Authors: Eileen Huang; Satish K Pillai; William A Bower; Katherine A Hendricks; Julie T Guarnizo; Jamechia D Hoyle; Susan E Gorman; Anne E Boyer; Conrad P Quinn; Dana Meaney-Delman Journal: Health Secur Date: 2015 Nov-Dec
Authors: Kenneth E Remy; Xizhong Cui; Yan Li; Junfeng Sun; Steven B Solomon; Yvonne Fitz; Amisha V Barochia; Mariam Al-Hamad; Mahtab Moayeri; Stephen H Leppla; Peter Q Eichacker Journal: Intensive Care Med Exp Date: 2015-02-28